---
title: "Updated 2026 Migraine Prevention Guidelines Reflect Expanded Treatment Options"
id: "stat-news-0-new-guidelines-on-migraine-prevention-reflect-increasing-options-for-patients"
canonical_url: "https://medichelpline.com/clinical-feed/stat-news-0-new-guidelines-on-migraine-prevention-reflect-increasing-options-for-patients"
content_type: "clinical_feed_article"
specialty: "Neurology"
source_name: "STAT News"
source_url: "https://www.statnews.com/2026/08/31/migraine-prevention-medication-guidelines/?utm_campaign=rss"
published_at: "2026-08-31T20:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Updated 2026 Migraine Prevention Guidelines Reflect Expanded Treatment Options
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/stat-news-0-new-guidelines-on-migraine-prevention-reflect-increasing-options-for-patients
- **Specialty:** [Neurology](https://medichelpline.com/clinical-feed/neurology.md)
- **Primary Source:** STAT News
- **Source URL:** [Original Journal Publication](https://www.statnews.com/2026/08/31/migraine-prevention-medication-guidelines/?utm_campaign=rss)
- **Published At:** 2026-08-31T20:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- New joint guidance from the American Headache Society (AHS) and the American Academy of Neurology (AAN) updates migraine prevention recommendations last revised in 2012. - The guidance highlights at least a half dozen medications approved by the FDA for migraine prevention since 2012, many targeting the **CGRP** pathway. - Authors recommend offering preventive therapy to patients with ≥4 migraine or severe headache days per month or those whose attacks substantially impair work or daily activities. - Chronic migraine is defined in the guidance as headache on ≥15 days per month for >3 months, with ≥8 days having migraine features. - Newer CGRP-targeting agents given favorable efficacy and tolerability ratings include **atogepant (Qulipta)**, **eptinezumab (Vyepti)**, **erenumab (Aimovig)**, **fremanezumab (Ajovy)**, and **galcanezumab (Emgality)**. - The guidelines continue to endorse older, well-studied options such as **botulinum toxin (Botox)** for chronic migraine, **propranolol** for episodic migraine, and **topiramate**, noting their longer-term safety data. - Recommendations call for clinicians to assess treatment response after 8–12 weeks. - The panel provided tailored recommendations for subgroups (high BMI, fibromyalgia, hypertension, pregnancy), but some recommendations may conflict with other specialty guidance and could complicate prescribing. - Rimegepant (Nurtec) and candesartan received more limited or lower recommendations despite existing evidence and tolerability; authors and external experts noted potential payer denial risks tied to layered qualification criteria. - The guideline development began in 2018, involved 19 specialists and Canadian experts, and noted that about one-third of the panel had relevant conflicts of interest and were restricted from rating evidence; conflict-free authors led guideline development. - An estimated 15% of Americans experience migraines; women are disproportionately affected. - Full guideline text is available via the published DOI referenced by the authors; specific methodological details, evidence grades, and some nuanced comparisons were reported in the source article.
## Clinical Analysis & Structured Key Points
[Skip to Main Content](https://www.statnews.com/2026/08/31/migraine-prevention-medication-guidelines/?utm_campaign=rss#wrapper) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo-white.svg) ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * Email this article * [Share this article](https://www.statnews.com/2026/08/31/migraine-prevention-medication-guidelines/?utm_campaign=rss) [Cancer](https://www.statnews.com/topic/cancer/) [Vaccines](https://www.statnews.com/topic/vaccines/) [research](https://www.statnews.com/topic/research/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) My Account * [Settings Complete your personal information for a more tailored experience ](https://www.statnews.com/my-account/) * [Billing](https://www.statnews.com/my-account/billing/) * [Log In](https://www.statnews.com/login/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) Reporting from the frontiers of health and medicine ](https://www.statnews.com/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Public Health](https://www.statnews.com/category/health/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Policy](https://www.statnews.com/category/politics/) * [Science](https://www.statnews.com/category/in-the-lab/) * [First Opinion](https://www.statnews.com/category/first-opinion/) * [STAT+](https://www.statnews.com/topic/stat-plus/) * [STAT Events](https://www.statnews.com/events/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) Search * [Log In](https://www.statnews.com/login/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [My Account](https://www.statnews.com/my-account/) [Home](https://www.statnews.com/) News * [Latest](https://www.statnews.com/latest/) * [Series & Investigations](https://www.statnews.com/stat-series-and-investigations-award-winning-journalism/) * Business * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Health Insurance](https://www.statnews.com/category/insurance/) * [Hospitals](https://www.statnews.com/category/hospitals/) * [Medical Devices](https://www.statnews.com/topic/medical-devices/) * Washington * [Policy](https://www.statnews.com/category/politics/) * [FDA](https://www.statnews.com/topic/fda/) * [NIH](https://www.statnews.com/topic/nih/) * Science * [CRISPR](https://www.statnews.com/topic/crispr/) * [Gene Therapy](https://www.statnews.com/topic/gene-therapy/) * [Neuroscience](https://www.statnews.com/topic/neuroscience/) * Public Health * [Addiction](https://www.statnews.com/topic/addiction/) * [Covid-19](https://www.statnews.com/topic/coronavirus/) * [Abortion](https://www.statnews.com/topic/abortion/) * [Health Disparities](https://www.statnews.com/topic/health-disparities/) * [Infectious Disease](https://www.statnews.com/topic/infectious-disease/) * [Mental Health](https://www.statnews.com/topic/mental-health/) * Disease * [Cancer](https://www.statnews.com/topic/cancer/) * [Cardiovascular Disease](https://www.statnews.com/topic/cardiovascular-disease/) * [Chronic Disease](https://www.statnews.com/topic/chronic-disease/) * [Diabetes](https://www.statnews.com/topic/diabetes/) * [Alzheimer's](https://www.statnews.com/topic/alzheimers/) * [Obesity](https://www.statnews.com/topic/obesity/) * Features * [Health Care Costs](https://www.statnews.com/health-insurance-costs-out-of-pocket-out-of-reach-series/) * [The Deadliest Drug](https://www.statnews.com/alcohol-epidemic-hiding-plain-sight-deadliest-drug-series/) * [Science, Shattered](https://www.statnews.com/american-science-shattered/) [Newsletters](https://www.statnews.com/signup/) [Opinion](https://www.statnews.com/category/first-opinion/) Columns * [Adam Feuerstein](https://www.statnews.com/category/adams-take/) * [Matthew Herper](https://www.statnews.com/category/matts-take/) * [Ed Silverman](https://www.statnews.com/category/pharmalot-view/) [Reports](https://reports.statnews.com/) [E-books](https://www.statnews.com/ebooks/) [Podcasts](https://www.statnews.com/podcasts/) [Tools & Trackers](https://www.statnews.com/trackers/) * [CRISPR Tracker](https://www.statnews.com/feature/crispr/tracker/) * [Breakthrough Device Tracker](https://www.statnews.com/feature/stat-plus/breakthrough-device-designation-fda-tracker/) * [Generative AI Tracker](https://www.statnews.com/feature/stat-plus/generative-ai-health-hospitals-tracker/) * [Obesity Drug Tracker](https://www.statnews.com/2023/09/12/new-weight-loss-drug-tracker-novo-nordisk-eli-lilly/) [Events](https://www.statnews.com/events/) * [Upcoming Events](https://www.statnews.com/events#upcoming-events) * [Summits](https://www.statnews.com/stat-summits/) [Community](https://www.statnews.com/community/) * [STAT Wunderkinds 2026](https://www.statnews.com/wunderkinds-nominate/) [Video](https://youtube.com/@Statnews) [Advertise](https://www.statnews.com/advertise/) * [STAT Brand Studio](https://sbs.statnews.com/) What's the word? Test your knowledge with our new weekday mini crossword [ Start solving ](https://www.statnews.com/stat-mini-crossword/) [Health](https://www.statnews.com/category/health/) # New guidelines on migraine prevention reflect increasing options for patients ## Since 2012, the FDA has approved a half dozen new medications * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * Email this article * [Share this article](https://www.statnews.com/2026/08/31/migraine-prevention-medication-guidelines/?utm_campaign=rss) ![](https://www.statnews.com/wp-content/uploads/2026/08/AdobeStock_1460280489-645x645.jpeg) Adobe ![](https://www.statnews.com/wp-content/uploads/2021/09/isabella-avatar-round-80x80.png) By [Isabella Cueto](https://www.statnews.com/staff/isabella-cueto/) Aug. 31, 2026 Chronic Disease Reporter ![](https://www.statnews.com/wp-content/uploads/2021/09/isabella-avatar-round-80x80.png) [Isabella Cueto](https://www.statnews.com/staff/isabella-cueto/) 1. [](https://www.linkedin.com/in/isabellacueto/ "Linkedin") 2. [](https://x.com/isabellacueto "X") isabella.cueto@statnews.com Isabella is a chronic disease reporter writing about how the Trump administration is tackling the nation’s health epidemic — or not. You can reach her on Signal at isabellacueto.03. [Subscribe](https://www.statnews.com/stat-plus/) or [log in](https://www.statnews.com/login/) to STAT+ to unlock email alerts New guidelines released Monday highlight the many new treatments that have hit the market in recent years for the prevention of migraine. The guidance for health care providers comes from the American Headache Society and the American Academy of Neurology, which last updated their recommendations in 2012. Advertisement “There has been a wealth of new treatment available,” said Rebecca Burch, guideline co-author and neurologist at the University of Vermont Medical Center. Burch also co-authored the previous guidance. Among the key updates are at least a half dozen medications that were approved for migraine prevention by the Food and Drug Administration since 2012. Many of those focus on blocking the calcitonin-gene related peptide, or CGRP, pathway, which is implicated in migraine. The [new guidelines](http://dx.doi.org/10.1212/WNL.0000000000214881) advise doctors to offer preventive treatment to people who have at least four migraine or severe headache days per month, or whose migraines interfere with their ability to work or complete daily tasks. An estimated [15% of Americans](https://pubmed.ncbi.nlm.nih.gov/38700185/) experience migraines, with women disproportionately affected. Many try to manage their pain with over-the-counter options once an attack has begun. Advertisement Related Story ![](https://www.statnews.com/wp-content/uploads/2024/08/AdobeStock_480234583-768x432.jpeg) ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [STAT Plus: To help migraine patients — and sell more medicines — major drugmakers turn to telehealth](https://www.statnews.com/2024/08/27/migraine-medication-direct-to-consumer-pharma-telehealth-portal-pfizer-for-all/) Preventive options can reduce the frequency of headache days, but many patients don’t know they qualify for those treatments. “We know from studies of the U.S. population that many more patients with migraine are eligible,” Burch said in a news conference. The guidelines include recommendations for less frequent, episodic migraines as well as chronic migraine, which is defined as headache on 15 or more days per month for over three months. At least eight of those headache days must include the features of a migraine, such as severe pain that lasts for hours or days. Migraine can also include nausea, aura, light sensitivity, or discomfort with loud sounds. Newer therapies, such as the CGRP-targeting medications atogepant (Qulipta), eptinezumab (Vyepti), erenumab (Aimovig), fremanezumab (Ajovy), and galcanezumab (Emgality), received high marks for their efficacy and tolerability. They were also recommended as a preventive option for patients who frequently rely on pain medication once their attacks begin. Some people experience a reduction in headache frequency once they taper down their acute pain medications. The guidelines also highlight older treatments, including Botox for chronic migraine, propranolol for episodic migraines, and the anti-seizure drug topiramate, that have more long-term safety data. Botox is well tolerated among migraine patients, according to studies the authors reviewed. Clinicians should check how well treatments are working after eight to 12 weeks, per the recommendations. “Guidelines are one way that groups like the AAN and the AHS can help improve patient outcomes,” Joanna Kempner, a sociology professor at Rutgers University, said. Kempner, who was not involved in the recommendations, studies the politics of pain and has written two books about headache disorders. “A strong recommendation provides physicians with much-needed ammunition in their fights for prior authorization.” However, better outcomes depend on patients’ ability to seek and afford health care, she said. Advertisement Related Story ![](https://www.statnews.com/wp-content/uploads/2025/06/AdobeStock_632516043-768x432.jpeg) ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [STAT Plus: GLP-1 reduced migraine frequency by nearly half, in a pilot study](https://www.statnews.com/2025/06/20/glp-1-drugs-cut-migraine-frequency-in-half-pilot-study-called-hugely-interesting/) That was top of mind for Andrew Charles, director of the UCLA Goldberg Migraine Program, as he read the new guidelines. (Charles was not involved in their creation, but is the immediate past president of the headache society, and knows several of the authors professionally.) The recommendations are sorted based on qualifications, like whether evidence of efficacy is a top concern versus tolerability or long-term safety. There are also separate recommendations for different categories of patients — those with a high body mass index, fibromyalgia, or hypertension, or who might be pregnant. “Frankly, I think it’s going to scare away primary care doctors from using it because of how complicated it is,” Charles said. In some places, the guidelines may cause confusion. For example, the scientific review found the tricyclic antidepressant amitriptyline to be a viable migraine treatment option for some pregnant patients. However, the American College of Obstetricians and Gynecologists advises against using tricyclic antidepressants during pregnancy due to the risk of major congenital abnormalities and other serious problems. In another instance, the guidelines recommend topiramate as an effective preventive migraine medication. It is also recommended as a good option for patients with a high BMI, since some studies show it can aid with weight loss. But topiramate is also known to cause birth defects, and can make hormonal birth control less effective when taken at higher doses. Clinicians would need to reconcile those contradictions to figure out the best treatment for their patients. Kempner and Charles both pointed out that candesartan, a generic hypertension medication often used to treat migraine in the U.S. and Europe, was dinged in the guidelines for having “insufficient evidence to support its use.” However, the drug is well tolerated, more affordable than other treatments, and has shown in several placebo-controlled studies to be effective at migraine prevention, Charles said. Advertisement Also downplayed was rimegepant, a CGRP-blocking medication sold under the brand name Nurtec, which was approved by the FDA in 2021 as a preventive treatment for episodic migraine. The guidelines recommend rimegepant for patients with episodic migraine only if they don’t respond to medications “with higher evidence.” “Payers will often find any reason they can to not approve access to a specific medication,” said Charles, who has worked as a consultant for several companies that make migraine treatments listed in the guidance. “If you create these multiple layers of qualifications, then that provides an opportunity for the payers to decline coverage.” The American Academy of Neurology did not return STAT’s request for comment. The process to update these guidelines began in January 2018, so various migraine treatments entered the field as the group reviewed the latest scientific evidence. Burch said the process took so long because there was a lot of literature to review. The group tasked with writing new recommendations included 19 headache specialists and researchers from around the U.S., plus several experts from Canada. About one-third of the panel had relevant conflicts of interest, so were not allowed to rate or review evidence, but voted along with the rest of the group on the recommendations. Conflict-free authors led the development of the guidelines. _STAT’s coverage of chronic health issues is supported by a grant from_[ _Bloomberg Philanthropies_](https://www.bloomberg.org/) _. Our_[ _financial supporters_](https://www.statnews.com/supporters/) _are not involved in any decisions about our journalism._ [neurology](https://www.statnews.com/topic/neurology/), [Physicians](https://www.statnews.com/topic/physicians/) [Submit a correction request](https://www.statnews.com/contact/?how_can_we_help_=Editorial%20Correction%20Request)[Reprints](https://www.parsintl.com/publications/stat/) 1. ![](https://www.statnews.com/wp-content/uploads/2021/09/isabella-avatar-round-80x80.png) [Isabella Cueto](https://www.statnews.com/staff/isabella-cueto/) 1. [](https://x.com/isabellacueto "X") 2. 3. [](https://www.linkedin.com/in/isabellacueto/ "Linkedin") Chronic Disease Reporter 1. [](https://x.com/isabellacueto "X") 2. 3. [](https://www.linkedin.com/in/isabellacueto/ "Linkedin") Isabella is a chronic disease reporter writing about how the Trump administration is tackling the nation’s health epidemic — or not. You can reach her on Signal at isabellacueto.03. ![](https://www.statnews.com/wp-content/themes/stat/images/article-new/envelope-open.svg) ![](https://www.statnews.com/wp-content/uploads/2023/06/Morning-Rounds-Logo-Black-640x295.png) ### Newsletter Understand how science, health policy, and medicine shape the world every day Please enter a valid email address. Sign Up Your data will be processed in accordance with our [Privacy Policy](https://www.statnews.com/privacy/) and [Terms of Service](https://www.statnews.com/terms-conditions/). You may opt out of receiving STAT communications at any time. Advertisement Most Popular 1. ![](https://www.statnews.com/wp-content/uploads/2026/08/GettyImages-2292466588-80x80.jpg) [Trump strikes nine more deals with drugmakers to lower prices](https://www.statnews.com/2026/08/31/trump-most-favored-nation-drug-pricing-new-round-price-cuts-announced/) 2. ![](https://www.statnews.com/wp-content/uploads/2026/08/AdobeStock_180917809-80x80.jpeg) [Nurse practitioner trainees find themselves stymied by shortage of clinical mentors](https://www.statnews.com/2026/08/24/nurse-practitioner-preceptor-shortage-clinical-placement-challenges/) 3. ![](https://www.statnews.com/wp-content/uploads/2015/11/PHARMALOT_LITTLE-copy-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [We’re reading about drug pricing deals, a new cancer therapy approval, and more](https://www.statnews.com/pharmalot/2026/08/31/drug-pricing-deals-polycythemia-vera-mimrylo-pharmalittle-newsletter/) 4. ![](https://www.statnews.com/wp-content/uploads/2026/08/AdobeStock_182456094-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [After a rough stretch, mRNA gets a boost — at least for now](https://www.statnews.com/2026/08/31/mrna-cancer-vaccine-intersects-politics-medicine/) 5. ![](https://www.statnews.com/wp-content/uploads/2026/08/marc-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Former Stanford president releases emails to rebut fraud and cover-up allegations in new book](https://www.statnews.com/2026/08/27/marc-tessier-lavigne-responds-theo-baker-book-misconduct-stanford-genentech/) #### [ Reports ](https://reports.statnews.com/) [ ![](https://www.statnews.com/wp-content/uploads/2026/08/2026_CancerReport_ReportCover-328x424.jpg) Explore Cancer’s transformational moments: KRAS, CAR-T, immunotherapy, and more ](https://reports.statnews.com/products/cancer-transformational-moments-advances-in-kras-car-t-immunotherapy) Advertisement #### [Events](https://www.statnews.com/events/) [ ![](https://www.statnews.com/wp-content/uploads/2026/07/924_Samsung_VirtualEvent_Wordpress_FeaturedImage-80x80.jpg) Biosimilars: Have We Reached an Inflection Point? Virtual Sep 24 ](https://www.statnews.com/event/biosimilars-what-is-next-virtual-event-sept-2026/) [ ![](https://www.statnews.com/wp-content/uploads/2026/01/Flagship2026_Wordpress_CalendarImageRegGoLive-1-80x80.jpg) 2026 STAT Summit Boston, MA Oct 14 ](https://www.statnews.com/event/2026-stat-summit/) [ ![](https://www.statnews.com/wp-content/uploads/2026/07/2026_DD_OfficeHours_VirtualEvent_Wordpress_CalendarImage-80x80.jpg) Office Hours with Isabella Cueto and Lev Facher Virtual Jul 29 ](https://www.statnews.com/event/deadliest-drug-series-office-hours-ama-july-2026/) Most Read in [STAT+](https://www.statnews.com/stat-plus/) 1. ![](https://www.statnews.com/wp-content/uploads/2026/08/Revmed_campus2-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [FDA approves new pancreatic cancer drug expected to usher in new era of treatment](https://www.statnews.com/2026/08/26/pancreatic-cancer-drug-rasonque-approved/) 2. ![](https://www.statnews.com/wp-content/uploads/2026/08/image-15-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Inside Moderna and Merck’s cancer vaccine triumph](https://www.statnews.com/2026/08/24
## Related Clinical Research

- [New ACC/AHA Guidance on Cardiovascular Care for Tactical Athletes](https://medichelpline.com/clinical-feed/stat-news-1-tactical-athletes-get-new-guidance-for-cardiovascular-fitness.md)
- [Cardiac-targeted delivery strategies for advanced therapies in heart disease](https://medichelpline.com/clinical-feed/pubmed-42284133.md) (DOI: 10.1093/eurheartj/ehag432)
- [Stopping Statins at Age 75 in Low‑Risk Adults: French Trial Found No Increase in Deaths](https://medichelpline.com/clinical-feed/stat-news-0-stopping-statins-in-people-over-75-at-low-risk-for-heart-disease-didn-t.md)
- [Modifiable risk factors linked to vulnerable coronary plaques: OCT study finds 5 drivers](https://medichelpline.com/clinical-feed/medical-news-today-0-5-modifiable-risk-factors-may-fuel-high-risk-plaques-linked-to-heart-attacks.md)
- [Diet and Alzheimer’s risk: Why no single best diet fits everyone](https://medichelpline.com/clinical-feed/medical-news-today-0-is-there-a-best-diet-to-help-lower-alzheimer-s-risk.md)

## Navigation
- [← Back to Neurology Feed](https://medichelpline.com/clinical-feed/neurology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.